Clinical Trials Logo
  1. Home
  2. Portal Vein Tumor Thrombus
  3. NCT03178656

A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis

Portal Vein Tumor Thrombus Clinical Trial

Official title:
RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib)

Clinical Trial Summary

According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so. According to our previous study, patients with hepatic carcinoma without portal vein tumor thrombus backbone and the contralateral tumor thrombus applyed tumor excision, along with tumor thrombus, the 3 year survival rate can reach 39.9%, the 5-year survival rate can reach 22.7%, curative effect is obviously better.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03178656
Study type Interventional
Source Huazhong University of Science and Technology
Contact Qiong Gong, Doctor
Phone +8618086496360
Email dtjgq486@hust.edu.cn
Status Recruiting
Phase Phase 4
Start date December 15, 2016
Completion date December 15, 2019
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04127396 - Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT Phase 4
Completed NCT01850368 - Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion Phase 2
Not yet recruiting NCT04319484 - Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Phase 2/Phase 3
Recruiting NCT02971345 - Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus Phase 3
Completed NCT04618367 - HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT N/A
Recruiting NCT06040177 - Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Phase 1/Phase 2
Completed NCT00849264 - Comprehensive Treatment for Different Types of Tumor Thrombi in the Portal Vein for Hepatocellular Carcinoma Patients Phase 2
Not yet recruiting NCT04069949 - Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus Phase 1/Phase 2